Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Assets: 2016-2024

Historic Assets for Organogenesis Holdings (ORGO) over the last 9 years, with Dec 2024 value amounting to $497.9 million.

  • Organogenesis Holdings' Assets rose 14.24% to $509.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $509.8 million, marking a year-over-year increase of 14.24%. This contributed to the annual value of $497.9 million for FY2024, which is 8.23% up from last year.
  • Per Organogenesis Holdings' latest filing, its Assets stood at $497.9 million for FY2024, which was up 8.23% from $460.0 million recorded in FY2023.
  • Organogenesis Holdings' Assets' 5-year high stood at $497.9 million during FY2024, with a 5-year trough of $290.2 million in FY2020.
  • Its 3-year average for Assets is $469.1 million, with a median of $460.0 million in 2023.
  • Data for Organogenesis Holdings' Assets shows a peak YoY spiked of 52.73% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Organogenesis Holdings' Assets stood at $290.2 million in 2020, then soared by 52.73% to $443.3 million in 2021, then rose by 1.38% to $449.4 million in 2022, then rose by 2.37% to $460.0 million in 2023, then increased by 8.23% to $497.9 million in 2024.